Study of Pfizer's Revatio in Sickle cell disease halted over safety issues
This article was originally published in Scrip
A clinical study testing Pfizer's Revatio (sildenafil) for the treatment of pulmonary hypertension in adults with sickle cell disease has been shut down by the National Heart, Lung, and Blood Institute (NHLBI) over safety concerns.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.